Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Exjade filed in Japan

April 3, 2007

Positive preclinical profile of the CRF1 antagonist MTIP in animal models of alcoholism

March 27, 2007

EVT-302 for smoking cessation begins clinical testing

March 26, 2007

Cleveland BioLabs to submit Protectan CBLB-502 in response to RFP

March 23, 2007

GTC grants expanded license to PharmAthene in support of Protexia

March 15, 2007

Enrollment complete in phase I/II study of ALKS-29 in alcohol dependence

March 8, 2007

Extended-release QuitPak begins pilot study for smoking cessation

Feb. 12, 2007

Virginia Commonwealth University and Nicogen jointly divulge novel antismoking agents

Feb. 6, 2007

Canadian approval for Champix

Jan. 29, 2007

Suboxone available in U.K.

Jan. 26, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.